ScoreComparison
Why is Akebia Therapeutics, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -9.74% and Operating profit at 14.90% over the last 5 years
2
The company has declared positive results in Mar'2025 after 2 consecutive negative quarters
- OPERATING CASH FLOW(Y) Highest at USD -2.42 MM
- RAW MATERIAL COST(Y) Fallen by -39.96% (YoY)
- NET SALES(Q) Highest at USD 62.47 MM
3
Risky - Negative Operating Profits
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -10.81%, its profits have fallen by -8.5%
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 15.98% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -10.81% returns
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Akebia Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Akebia Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Akebia Therapeutics, Inc.
-35.65%
0.61
84.80%
S&P 500
12.16%
0.81
19.85%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-9.74%
EBIT Growth (5y)
14.90%
EBIT to Interest (avg)
-8.82
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
3.69
Sales to Capital Employed (avg)
1.92
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
46.37%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
42.42
EV to EBIT
-51.46
EV to EBITDA
106.74
EV to Capital Employed
9.83
EV to Sales
6.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-19.11%
ROE (Latest)
-184.16%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend28What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -2.42 MM
RAW MATERIAL COST(Y)
Fallen by -39.96% (YoY
NET SALES(Q)
Highest at USD 62.47 MM
OPERATING PROFIT(Q)
Highest at USD 14.41 MM
PRE-TAX PROFIT(Q)
Highest at USD 7.23 MM
NET PROFIT(Q)
Highest at USD 7.23 MM
-9What is not working for the Company
INTEREST(HY)
At USD 14.6 MM has Grown at 214.27%
DEBT-EQUITY RATIO
(HY)
Highest at 250.65 %
Here's what is working for Akebia Therapeutics, Inc.
Pre-Tax Profit
At USD 7.23 MM has Grown at 163.86%
over average net sales of the previous four periods of USD -11.32 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 7.23 MM has Grown at 163.86%
over average net sales of the previous four periods of USD -11.32 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 62.47 MM has Grown at 35.14%
over average net sales of the previous four periods of USD 46.23 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -2.42 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 62.47 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 14.41 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 7.23 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 7.23 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by -39.96% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Akebia Therapeutics, Inc.
Interest
At USD 14.6 MM has Grown at 214.27%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at 250.65 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
